Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

Autores
Sanmamed, Miguel F.; Carranza Rua, Omar; Alfaro, Carlos; Oñate, Carmen; Martín Algarra, Salvador; Perez, Guiomar; Landazuri, Sara F.; Gonzalez, Alvaro; Gross, Stefanie; Rodriguez, Inmaculada; Muñoz Calleja, Cecilia; Rodríguez Ruiz, María; Sangro, Bruno; López Picazo, José M.; Rizzo, Manglio Miguel; Mazzolini Rizzo, Guillermo Daniel; Pascual, Juan I.; Andueza, Maria Pilar; Perez Gracia, Jose Luis; Melero, Ignacio
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden. Experimental Design: IL8 levelsweremonitored by sandwich ELISAs incultured tumor cells supernatants, tumor-xenograftedmice serum, and in samples from126 patients with cancer. Wecorrelated IL8 serumlevels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis. Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n = 16), renal cell carcinoma (RCC; n = 23), non-small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n = 16; RCC, n = 23; HCC, n = 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n = 16) and immunomodulatory monoclonal antibodies (melanoma, n = 8). IL8 concentrations in urine (n = 18) were mainly elevated in tumors with direct contact with the urinary tract. Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer. IL8 is a potentially useful biomarker to monitor changes in tumor burden following anticancer therapy, and has prognostic significance.
Fil: Sanmamed, Miguel F.. Universidad de Navarra; España
Fil: Carranza Rua, Omar. Universidad de Navarra; España
Fil: Alfaro, Carlos. Universidad de Navarra; España
Fil: Oñate, Carmen. Universidad de Navarra; España
Fil: Martín Algarra, Salvador. Universidad de Navarra; España
Fil: Perez, Guiomar. Universidad de Navarra; España
Fil: Landazuri, Sara F.. Universidad de Navarra; España
Fil: Gonzalez, Alvaro. Universidad de Navarra; España
Fil: Gross, Stefanie. University Hospital Erlangen; Alemania
Fil: Rodriguez, Inmaculada. Universidad de Navarra; España
Fil: Muñoz Calleja, Cecilia. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa; España
Fil: Rodríguez Ruiz, María. Universidad de Navarra; España
Fil: Sangro, Bruno. Universidad de Navarra; España
Fil: López Picazo, José M.. Universidad de Navarra; España
Fil: Rizzo, Manglio Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pascual, Juan I.. Universidad de Navarra; España
Fil: Andueza, Maria Pilar. Universidad de Navarra; España
Fil: Perez Gracia, Jose Luis. Universidad de Navarra; España
Fil: Melero, Ignacio. Universidad de Navarra; España
Materia
Il-8
Cancer
Serum Levels
Prognosis
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/37046
Acceder
id CONICETDig_e58df1facff8683e3f024d1fcac99cf8
oai_identifier_str oai:ri.conicet.gov.ar:11336/37046
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue originsSanmamed, Miguel F.Carranza Rua, OmarAlfaro, CarlosOñate, CarmenMartín Algarra, SalvadorPerez, GuiomarLandazuri, Sara F.Gonzalez, AlvaroGross, StefanieRodriguez, InmaculadaMuñoz Calleja, CeciliaRodríguez Ruiz, MaríaSangro, BrunoLópez Picazo, José M.Rizzo, Manglio MiguelMazzolini Rizzo, Guillermo DanielPascual, Juan I.Andueza, Maria PilarPerez Gracia, Jose LuisMelero, IgnacioIl-8CancerSerum LevelsPrognosishttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden. Experimental Design: IL8 levelsweremonitored by sandwich ELISAs incultured tumor cells supernatants, tumor-xenograftedmice serum, and in samples from126 patients with cancer. Wecorrelated IL8 serumlevels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis. Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n = 16), renal cell carcinoma (RCC; n = 23), non-small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n = 16; RCC, n = 23; HCC, n = 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n = 16) and immunomodulatory monoclonal antibodies (melanoma, n = 8). IL8 concentrations in urine (n = 18) were mainly elevated in tumors with direct contact with the urinary tract. Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer. IL8 is a potentially useful biomarker to monitor changes in tumor burden following anticancer therapy, and has prognostic significance.Fil: Sanmamed, Miguel F.. Universidad de Navarra; EspañaFil: Carranza Rua, Omar. Universidad de Navarra; EspañaFil: Alfaro, Carlos. Universidad de Navarra; EspañaFil: Oñate, Carmen. Universidad de Navarra; EspañaFil: Martín Algarra, Salvador. Universidad de Navarra; EspañaFil: Perez, Guiomar. Universidad de Navarra; EspañaFil: Landazuri, Sara F.. Universidad de Navarra; EspañaFil: Gonzalez, Alvaro. Universidad de Navarra; EspañaFil: Gross, Stefanie. University Hospital Erlangen; AlemaniaFil: Rodriguez, Inmaculada. Universidad de Navarra; EspañaFil: Muñoz Calleja, Cecilia. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa; EspañaFil: Rodríguez Ruiz, María. Universidad de Navarra; EspañaFil: Sangro, Bruno. Universidad de Navarra; EspañaFil: López Picazo, José M.. Universidad de Navarra; EspañaFil: Rizzo, Manglio Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Pascual, Juan I.. Universidad de Navarra; EspañaFil: Andueza, Maria Pilar. Universidad de Navarra; EspañaFil: Perez Gracia, Jose Luis. Universidad de Navarra; EspañaFil: Melero, Ignacio. Universidad de Navarra; EspañaAmerican Association for Cancer Research2014-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/mswordapplication/pdfhttp://hdl.handle.net/11336/37046Sanmamed, Miguel F.; Carranza Rua, Omar; Alfaro, Carlos; Oñate, Carmen; Martín Algarra, Salvador; et al.; Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins; American Association for Cancer Research; Clinical Cancer Research; 20; 22; 11-2014; 5697-57071078-0432CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://clincancerres.aacrjournals.org/content/20/22/5697.longinfo:eu-repo/semantics/altIdentifier/doi/10.1158/1078-0432.CCR-13-3203info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:43:38Zoai:ri.conicet.gov.ar:11336/37046instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:43:38.331CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
title Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
spellingShingle Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
Sanmamed, Miguel F.
Il-8
Cancer
Serum Levels
Prognosis
title_short Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
title_full Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
title_fullStr Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
title_full_unstemmed Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
title_sort Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
dc.creator.none.fl_str_mv Sanmamed, Miguel F.
Carranza Rua, Omar
Alfaro, Carlos
Oñate, Carmen
Martín Algarra, Salvador
Perez, Guiomar
Landazuri, Sara F.
Gonzalez, Alvaro
Gross, Stefanie
Rodriguez, Inmaculada
Muñoz Calleja, Cecilia
Rodríguez Ruiz, María
Sangro, Bruno
López Picazo, José M.
Rizzo, Manglio Miguel
Mazzolini Rizzo, Guillermo Daniel
Pascual, Juan I.
Andueza, Maria Pilar
Perez Gracia, Jose Luis
Melero, Ignacio
author Sanmamed, Miguel F.
author_facet Sanmamed, Miguel F.
Carranza Rua, Omar
Alfaro, Carlos
Oñate, Carmen
Martín Algarra, Salvador
Perez, Guiomar
Landazuri, Sara F.
Gonzalez, Alvaro
Gross, Stefanie
Rodriguez, Inmaculada
Muñoz Calleja, Cecilia
Rodríguez Ruiz, María
Sangro, Bruno
López Picazo, José M.
Rizzo, Manglio Miguel
Mazzolini Rizzo, Guillermo Daniel
Pascual, Juan I.
Andueza, Maria Pilar
Perez Gracia, Jose Luis
Melero, Ignacio
author_role author
author2 Carranza Rua, Omar
Alfaro, Carlos
Oñate, Carmen
Martín Algarra, Salvador
Perez, Guiomar
Landazuri, Sara F.
Gonzalez, Alvaro
Gross, Stefanie
Rodriguez, Inmaculada
Muñoz Calleja, Cecilia
Rodríguez Ruiz, María
Sangro, Bruno
López Picazo, José M.
Rizzo, Manglio Miguel
Mazzolini Rizzo, Guillermo Daniel
Pascual, Juan I.
Andueza, Maria Pilar
Perez Gracia, Jose Luis
Melero, Ignacio
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Il-8
Cancer
Serum Levels
Prognosis
topic Il-8
Cancer
Serum Levels
Prognosis
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden. Experimental Design: IL8 levelsweremonitored by sandwich ELISAs incultured tumor cells supernatants, tumor-xenograftedmice serum, and in samples from126 patients with cancer. Wecorrelated IL8 serumlevels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis. Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n = 16), renal cell carcinoma (RCC; n = 23), non-small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n = 16; RCC, n = 23; HCC, n = 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n = 16) and immunomodulatory monoclonal antibodies (melanoma, n = 8). IL8 concentrations in urine (n = 18) were mainly elevated in tumors with direct contact with the urinary tract. Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer. IL8 is a potentially useful biomarker to monitor changes in tumor burden following anticancer therapy, and has prognostic significance.
Fil: Sanmamed, Miguel F.. Universidad de Navarra; España
Fil: Carranza Rua, Omar. Universidad de Navarra; España
Fil: Alfaro, Carlos. Universidad de Navarra; España
Fil: Oñate, Carmen. Universidad de Navarra; España
Fil: Martín Algarra, Salvador. Universidad de Navarra; España
Fil: Perez, Guiomar. Universidad de Navarra; España
Fil: Landazuri, Sara F.. Universidad de Navarra; España
Fil: Gonzalez, Alvaro. Universidad de Navarra; España
Fil: Gross, Stefanie. University Hospital Erlangen; Alemania
Fil: Rodriguez, Inmaculada. Universidad de Navarra; España
Fil: Muñoz Calleja, Cecilia. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa; España
Fil: Rodríguez Ruiz, María. Universidad de Navarra; España
Fil: Sangro, Bruno. Universidad de Navarra; España
Fil: López Picazo, José M.. Universidad de Navarra; España
Fil: Rizzo, Manglio Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pascual, Juan I.. Universidad de Navarra; España
Fil: Andueza, Maria Pilar. Universidad de Navarra; España
Fil: Perez Gracia, Jose Luis. Universidad de Navarra; España
Fil: Melero, Ignacio. Universidad de Navarra; España
description Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden. Experimental Design: IL8 levelsweremonitored by sandwich ELISAs incultured tumor cells supernatants, tumor-xenograftedmice serum, and in samples from126 patients with cancer. Wecorrelated IL8 serumlevels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis. Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n = 16), renal cell carcinoma (RCC; n = 23), non-small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n = 16; RCC, n = 23; HCC, n = 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n = 16) and immunomodulatory monoclonal antibodies (melanoma, n = 8). IL8 concentrations in urine (n = 18) were mainly elevated in tumors with direct contact with the urinary tract. Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer. IL8 is a potentially useful biomarker to monitor changes in tumor burden following anticancer therapy, and has prognostic significance.
publishDate 2014
dc.date.none.fl_str_mv 2014-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/37046
Sanmamed, Miguel F.; Carranza Rua, Omar; Alfaro, Carlos; Oñate, Carmen; Martín Algarra, Salvador; et al.; Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins; American Association for Cancer Research; Clinical Cancer Research; 20; 22; 11-2014; 5697-5707
1078-0432
CONICET Digital
CONICET
url http://hdl.handle.net/11336/37046
identifier_str_mv Sanmamed, Miguel F.; Carranza Rua, Omar; Alfaro, Carlos; Oñate, Carmen; Martín Algarra, Salvador; et al.; Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins; American Association for Cancer Research; Clinical Cancer Research; 20; 22; 11-2014; 5697-5707
1078-0432
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://clincancerres.aacrjournals.org/content/20/22/5697.long
info:eu-repo/semantics/altIdentifier/doi/10.1158/1078-0432.CCR-13-3203
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/msword
application/pdf
dc.publisher.none.fl_str_mv American Association for Cancer Research
publisher.none.fl_str_mv American Association for Cancer Research
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082942675189760
score 13.22299

Publicaciones similares